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Background: Adequate coverage is key to the success of human papillomavirus (HPV) vaccination programmes.
There is currently no organised HPV vaccination programme in Germany. The aim of this analysis was to determine
HPV vaccine uptake as well as factors associated with uptake in nine to 17 year-old girls in Germany during the first
year of vaccine availability.
Methods: This analysis is based on data from the Healthcare Access Panel, an established population-based
household panel consisting of 55 000 representative households in Germany who were contacted between
September and October 2007. A total of 4 747 households included at least one girl aged nine to 17 years. After
reading a description of the HPV vaccine, these girls were asked, “Would you have yourself vaccinated against
HPV?” Logistic regression analyses were performed to investigate associations between vaccination status and
socio-demographic characteristics of the girls and their mothers.
Results: Of the 4 747 girls in the households who received questionnaires, 2 224 (46.9 %) participated in the study
and 1 906 (40.2 %) answered the vaccination question. A total of 17.4 % of the girls were already vaccinated, 61.5 %
felt positively about doing so, 4.7 % said they would not be vaccinated, and 16.3 % were not sure. The probability
of a girl being vaccinated increased with each additional year of age (Odds Ratio (OR): 1.6, 95 % Confidence Interval
(CI) 1.5–1.7). Among the 17 year-old girls, 38.5 % (95 % CI 32.6–44.4 %) had been vaccinated. Having a mother with
high education (OR: 1.5, 95 % CI 1.0–2.3) or medium education (OR: 1.5, 95 % CI 1.1–2.1) versus basic education was
a significant predictor for having been vaccinated. Similarly, medium (OR: 1.5, 95 % CI 1.0–2.4) versus low SES was
significantly associated with having been vaccinated. Our analysis showed that during the first year of HPV vaccine
availability in Germany, vaccination uptake was low.
Conclusions: Countries with organised HPV vaccination programmes showed much higher vaccination uptake,
even in the first year after programme introduction. If vaccination uptake in Germany is to significantly improve in
the future, an organised vaccination programme will need to be introduced.
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HPV infection is causally associated with the development
of cervical cancer, which is the fourth most common can-
cer among women worldwide [1]. In 2012, more than 67
000 women in Europe were diagnosed with cervical can-
cer and more than 28 000 women died from the disease
[1]. Efforts to prevent HPV infection, including HPV* Correspondence: sekretariat.klug@tum.de
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to potentially reduce the risk of cervical cancer [2].
Among the more than 100 types of human papilloma-
virus (HPV), there are approximately 40 which infect the
genital tract [3]. Fifteen HPV subtypes have been classi-
fied as high risk for cervical cancer development [4]. In
particular, HPV 16 and 18 have been strongly associated
with cervical cancer [4, 5]. Among the HPV subtypes
classified as low risk, HPV 6 and 11 are associated with
causing benign genital warts [4, 6].
In 2006, the European Medicines Agency (EMA) and
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6, 11, 16 and 18. This was followed by EMA and FDA
approval in 2007 and 2009 respectively for a bivalent
vaccine that protects against HPV 16 and 18 only. In
Germany, a recommendation was issued by the German
Standing Committee on Vaccination (STIKO) in March
2007 to vaccinate girls aged 12–17 [7]. In 2014, this rec-
ommendation was revised, stating that girls between the
ages of nine and 14 should be vaccinated prior to first
sexual activity [8]. The cost of the vaccine for girls in the
recommended age range is covered by the German
health insurance system, in which membership is largely
mandatory. Girls may get vaccinated when they visit a
paediatrician, gynecologist or general practitioner. However,
in Germany there is no organised vaccination programme
and high coverage among the target age groups has yet to
be achieved.
In some countries, such as the United Kingdom,
Canada and Australia, there are ongoing school-based
programmes for HPV vaccine delivery [9]. In other coun-
tries, such as the Netherlands, population-based, non-
school-based programmes have been started [10]. Vaccine
uptake has varied widely between different countries [11].
Studies have identified various reasons for refusing to
have oneself or ones child vaccinated. Belief in the safety
of vaccines in general, as well as perceived susceptibility
to HPV infection or cervical cancer have been shown to
correlate with acceptance of the HPV vaccine [12–14].
Age of the parents and region of residence were found
to be associated with intention to vaccinate a daughter
in a Canadian study [15]. Studies have shown inconsistent
findings with regards to the association between house-
hold income and HPV vaccination acceptance [16, 17].
This analysis aimed to determine the uptake of the
HPV vaccine among girls aged nine to 17 years in
Germany and to determine factors associated with uptake.
The study was conducted during the first year of vaccine
availability in Germany and therefore provides valuable
baseline data, which can be compared to future studies




This cross-sectional analysis is based on data from the
Healthcare Access Panel, an established population-based
household panel consisting of 55 000 representative
households in Germany who were contacted between
September and October 2007. Households were routinely
recruited to the panel and the base sample was evaluated
on an ongoing basis. Any underrepresented cells were
purposively recruited for to ensure representativeness of
the base population. A total of 4 747 households in the
panel were identified as including at least one girl agednine to 17 years. These households received an additional
question on HPV vaccination, which was included in the
standard panel questionnaire. All questionnaires were
mailed to the parents via the regular postal service and
parents consented to their daughters filling out the
question relating to HPV vaccination within the home
environment.Questionnaire
The HPV vaccination question was introduced with the
following explanatory paragraph:
“A prophylactic vaccine against human papillomavirus
(HPV) is now available. The vaccine is supposed to
prevent cervical cancer as well as genital warts. For
girls between the age of 12 and 17 the cost of the
vaccination is covered by health insurance.”
Girls between the ages of nine and 17 were asked:
“Would you have yourself vaccinated against HPV?” This
question had five response categories: “Already been vac-
cinated”, “Yes, vaccination will occur”, “Yes, vaccination is
a possibility”, “No”, and “I am not sure”.Education, income and socio-economic status (SES)
Due to the fact that girls below the age of 18 are usually
still attending school and living at home, data on educa-
tion, net household income and profession included in
this analysis were retrieved from the mother’s responses
to these three questionnaire items.
SES was determined using an approach developed by
Winkler, combining data on education, net household
income and profession [18]. The index was then modified
to take the number of people living in each household into
account [19]. The education, household income and pro-
fession variables were each reduced to seven categories,
and assigned one to seven points. The resulting scores
were summed to give a final score between three and 21.
These scores were categorised into three SES levels: low
(score < 8.5), medium (score ≥ 8.5 and <14.5), and high
SES (score ≥ 14.5). If data were missing for one of the
three variables, imputation was used to obtain the mean
of the two available variables [20].
Education, income and SES are known to have a signifi-
cant effect on overall health outcomes. Maternal education
and income were therefore also investigated separately in
this analysis. With regards to education, pupils in Germany
may complete one of three types of secondary education.
Gymnasium (12–13 years) allows entry into university,
while Realschule is completed after 10 years and
Hauptschule after 9 years. These three types of school
education were classified as follows in our study: high
education, medium education and basic education.
Table 1 Socio-demographic characteristics of 1 906 responding
girls aged 9 to 17 years and their mothers















Eastern Germany 288 15.1
Western Germany 1618 84.9
Highest school education of mother
Basic education 461 24.2
Medium education 975 51.2
High education 407 21.4
Missing 63 3.3
Net monthly household income
< 1500€ 402 21.1
1500€ to 2999€ 1024 53.7
≥ 3000€ 455 23.9
Missing 25 1.3
SES of mother
Low SES 210 11.0
Medium SES 1397 73.3
High SES 154 8.1
Missing 145 7.6
Total 1906 100
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medium (1500€ to 2999€) or low (<1500€).
Statistical analysis
Anonymised data on the girls’ age and nationality, the
mother’s socio-demographic characteristics as well as the
girls’ responses to the vaccination question were available
for this analysis. The actual vaccine uptake of girls aged
nine to 17 was analyzed. Univariable and multivariable lo-
gistic regression analyses were performed to determine
factors associated with vaccination uptake. One model
included age (as a continuous variable), residence in
eastern versus western Germany (reference: western
Germany), education (reference: basic education) and in-
come (reference: low income); the second model included
the same variables, except that SES (reference: low SES)
was included instead of education and income. Due to the
fact that the SES variable was constructed from the educa-
tion, income and profession variables, this necessitated
the inclusion of these variables in separate logistic regres-
sion models in order to avoid collinearity.
Odds ratios (OR) and 95 % confidence intervals (CI)
were reported, and p-values less than 0.05 were consid-
ered statistically significant. All analyses were performed
by two independent researchers, one using STATA/SE
8.1 (College Station, Texas, USA) for Windows (2003), and
the other using SAS 9.1.3 (Cary, North Carolina, USA).
Results
Among the 4 747 households with a girl aged nine to 17
included in the survey, 2 224 (46.9 %) returned the ques-
tionnaire. Since 318 girls had not answered the HPV
vaccination question, 1 906 (40.2 %) questionnaires were
available for analysis. The age distribution of the study
sample ranged from 8.9 % nine year-olds to 14.5 %
17 year-olds (Table 1). Most girls (87.4 %) had German
citizenship and resided in western Germany (84.9 %).
Concerning school education, 21.4 % of the girls’
mothers had high education, 51.2 % medium education,
and 24.2 % basic education. The majority of households
were in the medium income (1500€ to 2999€) category
(53.7 %). About eight percent had mothers in the high
SES category, 73.3 % in the medium SES category, 11 %
in the low SES category, and 7.6 % of mothers provided
insufficient data to determine SES.
As shown in Table 2, 17.4 % (95 % CI 15.7–19.2 %) of
girls aged nine to 17 indicated they had already been
vaccinated, 35.4 % (95 % CI 33.3–37.6 %) said that vac-
cination will occur, and 26.1 % (95 % CI 24.2–28.2 %)
said it was a possibility. Only 90 girls (4.7 %, 95 % CI
3.8–5.8 %) indicated that they would not be vaccinated,
while 311 (16.3 %, 95 % CI 14.7–18.1 %) were not sure.
Those who were either already vaccinated or had a
positive attitude towards HPV vaccination (‘vaccinationwill occur’ or ‘vaccination is a possibility’) ranged be-
tween 57.7 % (95 % CI 49.8–65.2) (among 9 year-olds)
and 86.4 % (95 % CI 81.8–90.2 %) (among 16 year-olds)
(Fig. 1). However, among nine, ten and 11 year-olds,
who were not covered by the national vaccination rec-
ommendation at the time, only 0.6 %, 1.1 % and 1.1 %
respectively had been vaccinated. For girls 12 years and
older, the proportion of vaccinated girls was considerably
larger, and increased with each additional year of age. The
15 and 16 year-olds had similar HPV vaccination uptake
(27.1 %, 95 % CI 21.3–33.5 % and 27.6 %, 95 % CI 22.4–
33.2 % respectively), while 38.5 % (95 % CI 32.6–44.4 %)
Table 2 Responses to the question “Would you have yourself
vaccinated against HPV?”, which was answered by 1 906 girls
aged 9 to 17
Would you have yourself
vaccinated against HPV?
Girls (aged 9–17)
n % 95 % CIa
Already been vaccinated 332 17.4 15.7 - 19.2
Vaccination will occur 675 35.4 33.3 - 37.6
Vaccination is a possibility 498 26.1 24.2 - 28.2
No 90 4.7 3.8 - 5.8
I am not sure 311 16.3 14.7 - 18.1
Total 1906 100
aCI: Confidence Interval
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cine uptake among the 12 to 17 year-olds was 23.8 %
(95 % CI 21.6–26.1 %).
Results of the univariable logistic regression analyses
showed that with each increasing year of age, the likeli-
hood of a girl having already been vaccinated increased
(OR: 1.6, 95 % CI 1.5–1.7). Girls living in eastern
Germany were more likely to have been vaccinated than
those living in western Germany (OR: 1.4, 95 % CI 1.0–
1.9). Additionally, having a mother with high education
(OR: 1.6, 95 % CI 1.1–2.3) or medium education (OR:
1.4, 95 % CI 1.0–1.9) as compared to basic education,
was statistically significantly associated with having been
vaccinated (Table 3). Girls with mothers who had a high
income were also more likely to have been vaccinated
(OR: 1.5, 95 % CI 1.0–2.1) than those with a low income.
Because the SES variable included the education and in-
come variables as two of its components, two different
multivariable logistic regression analyses were performed,
one including education and income, and the otherFig. 1 Vaccination status of girls and distribution of responses (%) by age fincluding SES. The multivariable logistic regression model
including age, area of residence, education and income
showed that girls whose mother had high education (OR:
1.5, 95 % CI 1.0–2.3) were more likely to have already
been vaccinated compared to those whose mother had a
basic education (Table 3). A similar statistically significant
effect was found when comparing daughters of mothers
with medium education (OR: 1.5, 95 % CI 1.1–2.1) to
those with basic education. When SES was included in the
multivariable model instead of education and income, girls
of mothers with medium SES (OR: 1.5, 95 % CI 1.0–2.4)
were more likely to have been vaccinated compared to
girls of mothers with low SES. Age of the girl remained a
statistically significant predictor in both multivariable
models, with an increased likelihood of being vaccinated
per year of increased age (OR: 1.6, 95 % CI 1.5–1.7).
Discussion
To our knowledge, this is the first study on the influence
of maternal education, household income and SES on
the actual uptake of the HPV vaccine among girls in
Germany during the first year of vaccine availability. Pre-
vious international studies have examined the influence of
various factors on the intention to immunise a child
[16, 21–23]. Studies have also been conducted on factors
influencing actual vaccine uptake, although most of these
studies were conducted in the United States [11].
The uptake of the HPV vaccine in this German popula-
tion of girls aged nine to 17 years was 17.4 %. Although at
the time of the survey the STIKO recommended immu-
nising girls aged 12–17 against HPV [7], only 23.8 % of
girls in this age group reported that they had already been
vaccinated during the first year of vaccine availability.
Across all ages, our results showed that older girls wereor 1 906 girls
Table 3 Results of Univariable and Multivariable logistic regression analyses for girls already vaccinated versus girls who had not
been vaccinateda
Univariable Multivariable including educationb Multivariable including SESc
Variable ORj 95 % CIk ORj 95 % CIk ORj 95 % CIk
Age of the girld 1.6 1.5–1.7 1.6 1.5–1.7 1.6 1.5–1.7
Residence in eastern Germanye 1.4 1.0–1.9 1.3 0.9–1.9 1.3 0.9–1.8
High Education (mother)f 1.6 1.1–2.3 1.5 1.0–2.3 - -
Medium Education (mother)f 1.4 1.0–1.9 1.5 1.1–2.1 - -
High Income (mother)g 1.5 1.0–2.1 1.3 0.9–2.0 - -
Medium Income (mother)g 1.1 0.8–1.4 1.1 0.8–1.6 - -
High SES (mother)h 1.5 0.9–2.6 - - 1.7 0.9–3.0
Medium SES (mother)h 1.3 0.9–2.0 - - 1.5 1.0–2.4
aModels show the odds ratios for girls indicating ‘Already been vaccinated’ versus ‘Vaccination will occur’, ‘Vaccination is a possibility’, ‘No’ or ‘I am not sure’ for the
question ‘Would you have yourself vaccinated against HPV?’
bModel controlled for age, region of residence, education and income








Schülein et al. BMC Public Health  (2016) 16:995 Page 5 of 8more likely than younger girls to have been vaccinated,
and that girls whose mothers had a high education,
medium education or medium SES were more likely to
have already been vaccinated than those whose mothers
had a basic education or low SES. Region of residence and
income were not found to have a statistically significant
effect in the multivariable models.
A German survey conducted between 2009 and 2011
reported that 39.5 % of girls aged 14–17 had received
the three-dose course of the HPV vaccine [24], while an-
other German study conducted in 2010 reported that
49 % of women aged 18–20 had been vaccinated [25].
Similarly to Germany, France offers vaccination on re-
quest and achieved only 24 % coverage with three doses
among 14 year-old girls in 2008 [26]. In the United
States in 2007, it was estimated that 25.1 % of girls aged
13 to 17 had received at least one of the three required
doses, and a fourth of those had completed the full vac-
cine course [27]. The 2007 California Health Interview
Survey (CHIS) found that 26 % of girls aged between 13
and 17 had received at least one dose of the HPV vaccine,
and 11 % had completed the series of three doses [28].
The Californian study also asked teenagers about their
intention to be vaccinated, and 76 % of non-vaccinated 13
to 17 year-olds indicated that they were interested in being
vaccinated [28]. These data are similar to our findings,
where 74.5 % of girls aged nine to 17 who had not yet
been vaccinated were open to the idea or had plans to do
so. Vaccination in the United States has improved since
the vaccine was first introduced, with the Centers for
Disease Control and Prevention (CDC) reporting thatin 2010, 32 % of girls aged between 13 and 17 had re-
ceived three doses of the vaccine [29].
Australia, Scotland and England, in contrast to
Germany, the United States and France, have implemented
nationwide organised, school-based HPV immunisation
programmes and therefore have direct access to the target
population. Australia, which implemented a school-based
programme in 2007, had achieved an average three-dose
coverage for girls aged 12 of between 64 and 80 % by 2009
[30]. The National Health Services of Scotland reported
that, after implementing a school-based vaccination
programme, 88 % of girls in the second, fifth and sixth
years of secondary school (approximate ages 13, 16 and 17)
received the first two vaccine doses between September
2008 and February 2009 [31]. September 2011 figures from
Scotland reported that 92 % of girls progressing through
the system had received a first dose, with 81 % completing
the course [32]. Similarly, within a school-based immunisa-
tion programme, 70.6 % of 2 817 grade eight girls at sec-
ondary schools in Manchester, England had received the
first dose of the HPV vaccine, and 68.5 % had also received
the second [33]. Three-dose coverage in England was
reported to be 76 % in 2010 [34]. The Netherlands,
which has a population-based, non-school-based HPV
vaccination programme, reported 49.9 % coverage for
the first dose among girls aged 13–16 after starting
their programme in March 2009 [10]. In 2011, coverage
in the Netherlands was reported to be 58 % among 12–
13 year-old girls [26].
Multivariable models in our study showed that girls
whose mothers had high education (OR: 1.5, 95 % CI
Schülein et al. BMC Public Health  (2016) 16:995 Page 6 of 81.0–2.3) were more likely to have already been vaccinated
compared to those whose mothers had basic education.
Rosenthal and colleagues, however, found no significant
association between the mother’s education and the
daughter’s vaccination uptake in a study conducted in the
United States [35]. Other studies in the United States and
Canada investigated the association of parental (mothers
and fathers) education on HPV vaccine uptake, with in-
consistent findings [23, 36, 37]. Brewer and colleagues
found higher vaccine uptake in girls of parents with a col-
lege education compared to a high school education [37].
Chao and colleagues reported that higher neighbourhood
education level was positively associated with vaccine regi-
men completion in California [38].
Our findings showed that girls of mothers with medium
SES (OR: 1.5, 95 % CI 1.0–2.4) were more likely to have
been vaccinated compared to girls of mothers with low
SES. Findings from another German study revealed an in-
creased likelihood of being vaccinated among girls from
medium SES, compared to high SES, families (OR: 1.9,
95 % CI 1.3–2.8) [24].
Low vaccine coverage potentially limits the impact of
the HPV vaccine on the reduction of cervical cancer in-
cidence and mortality [39]. Several studies have con-
cluded the vaccine to be cost-effective, but these studies
assumed vaccine coverage rates to be at least 50 % or
higher [40, 41]. Part of maximising the cost-effectiveness
of the HPV vaccine therefore involves achieving high
coverage in young adolescent girls [42].
Limitations of our study include using self-reported
data. It could be argued that very young girls may have
had difficulty understanding the question relating to
HPV vaccination. However, the girls filled out the ques-
tionnaire within their home environment, with the con-
sent of their parents, and could have asked their parents
to clarify any parts of the question which may have been
unclear. No data were collected regarding how many of
the girls who indicated being vaccinated had actually
completed the full course of three vaccination doses. In
addition, information regarding reasons why a girl was
not vaccinated was not available. Although almost 2 000
girls aged nine to 17 filled out the questionnaire, the re-
sponse rate of 40.2 % was relatively low. In order to de-
termine the potential selection bias introduced by this
fairly low response rate, we assessed households with a
child (boy or girl) aged younger than 18 years based on
2007 data from the Federal Statistical Office [43] and
found a very similar distribution of household income
when comparing the households included in our analysis
with this subgroup in the German population. A total of
79 % of households included in our analysis had an in-
come of 1500 € or more, compared to 81 % of households
with a child aged younger than 18 years in the German
population as a whole. We therefore did not considerweighting to be necessary in our analyses. A further
limitation is that our data only allowed assessment of
the mother’s and not the father’s SES and education.
Nevertheless, the ‘mother’s SES’ variable includes ‘house-
hold income’ and in households where there was a father,
this variable would also have taken the father’s income
into account. Although the role of the mother is of pri-
mary importance in terms of communicating HPV-related
issues with the daughter, the father may have also played
an important role in terms of decision-making within the
household [44]. It is important to note that the HPV vac-
cine had only been available in Germany for approxi-
mately one year when this survey was conducted.
Conclusions
Although vaccination rates in Germany have increased
over the past few years, the rates remain low. Other coun-
tries with organised, school-based programmes introduced
the vaccine at approximately the same time and have had
much higher uptake rates during the first year following
vaccination introduction, as well as in subsequent years. If
higher vaccination rates are to be achieved in Germany,
an organised HPV vaccination programme, ideally school-
based, will need to be introduced. Additionally, reasons
why girls or their parents might decide against vaccination
should be investigated. Consideration should be given to
strategies aimed at reaching the population groups identi-
fied in this study that were less likely to be vaccinated,
such as younger girls and girls whose mothers have lower
levels of education and SES. High vaccination uptake is
necessary to reduce the incidence of cervical cancer, and
organised vaccination programmes would help to achieve
this goal.
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